Vera Therapeutics, Inc. (VERA) stock
VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
$28.10−0.94 (-3.24%)
Close on Nov 13, 2026Market cap $2.02BP/E –Yield –
Vera Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Vera Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $246.65M, up 30.3% year over year. For fiscal 2025 it was $215.26M, up 70.6% from the year before. The highest annual figure on record is $215.26M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $215.26M | +70.6% |
| FY2024 | Dec 31, 2024 | $126.17M | +61.3% |
| FY2023 | Dec 31, 2023 | $78.23M | +13.4% |
| FY2022 | Dec 31, 2022 | $68.99M | +206.9% |
| FY2021 | Dec 31, 2021 | $22.48M | -50.3% |
| FY2020 | Dec 31, 2020 | $45.21M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.25M | -27.0% |
| Q2 FY2026 | Jun 30, 2026 | $60.08M | +3.2% |
| Q1 FY2026 | Mar 31, 2026 | $86.01M | +108.4% |
| Q4 FY2025 | Dec 31, 2025 | $59.31M | +77.9% |
| Q3 FY2025 | Sep 30, 2025 | $56.47M | +40.1% |
| Q2 FY2025 | Jun 30, 2025 | $58.20M | +98.5% |
| Q1 FY2025 | Mar 31, 2025 | $41.28M | +77.9% |
| Q4 FY2024 | Dec 31, 2024 | $33.35M | +60.4% |
| Q3 FY2024 | Sep 30, 2024 | $40.31M | +150.4% |
| Q2 FY2024 | Jun 30, 2024 | $29.31M | +80.6% |
| Q1 FY2024 | Mar 31, 2024 | $23.20M | -7.6% |
| Q4 FY2023 | Dec 31, 2023 | $20.79M | -22.1% |
| Q3 FY2023 | Sep 30, 2023 | $16.10M | -18.1% |
| Q2 FY2023 | Jun 30, 2023 | $16.23M | +60.5% |
| Q1 FY2023 | Mar 31, 2023 | $25.11M | +100.1% |
| Q4 FY2022 | Dec 31, 2022 | $26.68M | +109.2% |
| Q3 FY2022 | Sep 30, 2022 | $19.66M | +451.5% |
| Q2 FY2022 | Jun 30, 2022 | $10.11M | +212.6% |
| Q1 FY2022 | Mar 31, 2022 | $12.55M | +328.0% |
| Q4 FY2021 | Dec 31, 2021 | $12.75M | -68.0% |
| Q3 FY2021 | Sep 30, 2021 | $3.56M | +81.0% |
| Q2 FY2021 | Jun 30, 2021 | $3.24M | +65.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.93M | +103.8% |
| Q4 FY2020 | Dec 31, 2020 | $39.84M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.97M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.95M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.44M | – |
See a number that looks wrong?